Enfusion, Inc. (NYSE:ENFN) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its position in Enfusion, Inc. (NYSE:ENFN - Free Report) by 57.5% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 524,142 shares of the company's stock after purchasing an additional 191,436 shares during the quarter. Dimensional Fund Advisors LP owned about 0.41% of Enfusion worth $4,466,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Brown Capital Management LLC boosted its stake in Enfusion by 6.5% during the fourth quarter. Brown Capital Management LLC now owns 11,817,661 shares of the company's stock worth $114,631,000 after buying an additional 724,502 shares during the period. Vanguard Group Inc. increased its holdings in Enfusion by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 3,653,189 shares of the company's stock valued at $33,792,000 after purchasing an additional 51,670 shares during the last quarter. Wasatch Advisors LP raised its position in Enfusion by 34.2% in the first quarter. Wasatch Advisors LP now owns 792,083 shares of the company's stock valued at $7,327,000 after purchasing an additional 201,771 shares during the period. Wellington Management Group LLP lifted its stake in Enfusion by 5.7% during the fourth quarter. Wellington Management Group LLP now owns 489,364 shares of the company's stock worth $4,747,000 after purchasing an additional 26,464 shares in the last quarter. Finally, Scalar Gauge Management LLC purchased a new position in shares of Enfusion during the fourth quarter worth $1,993,000. Hedge funds and other institutional investors own 81.05% of the company's stock.

Enfusion Stock Performance

Shares of NYSE ENFN traded down $0.03 during trading on Thursday, reaching $8.95. The stock had a trading volume of 188,384 shares, compared to its average volume of 375,751. The business's 50-day moving average price is $8.49 and its 200-day moving average price is $8.89. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $10.45. The company has a market cap of $1.15 billion, a P/E ratio of 298.33, a PEG ratio of 2.63 and a beta of 0.92.

Enfusion (NYSE:ENFN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). Enfusion had a return on equity of 6.17% and a net margin of 1.98%. The business had revenue of $49.46 million for the quarter, compared to analysts' expectations of $50.27 million. Analysts forecast that Enfusion, Inc. will post 0.07 EPS for the current fiscal year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.